Connect with Industry
Virtual Patent Awards Ceremony 2021:
“Innovation in the Time of COVID-19: Meeting the Challenge” – If you missed it, catch the full event here!
Continuity of Service
Our office remains committed to providing our standard level of excellent service. At this time, due to the fluid situation of the coronavirus pandemic, we will do so virtually, rather than in-person, during our regular business hours. To reach the Office of Technology Commercialization, please call 202.687.7424 or email email@example.com and Jeremy Alexander at firstname.lastname@example.org . Someone will respond to you promptly.
More information on COVID-19 related agreements can be found on the following link: https://otc.georgetown.edu/covid19-contracts/
Office of Technology Commercialization (OTC) manages Georgetown University invention disclosures, patenting and licensing activities, research collaboration agreements, material transfer agreements, confidentiality agreements, data use agreements, copyright and intellectual property agreements between the University and faculty, engagement of Georgetown University in the founding of startup companies, and assistance to University entrepreneurs in starting their own companies. If you believe that you have an invention, it is critical that you disclose the invention to OTC immediately, and prior to any publication or public presentation of the invention.
- About Us
- For Georgetown Inventors – Reporting an invention and other resources
- Industry Collaboration Opportunities for Georgetown Principal Investigators
- For Industry – Technology Licensing Opportunities
- Startup Guidance – For Georgetown Inventors and Entrepreneurs
- Events – List of events we host throughout the year
Top Stories From OTC
Upcoming I2Is and Events:
Tuesday, July 27, 2021 12:00 am – 1:00 pm – Virtual Zoom Event: “Entrepreneur Education and Business Networking Program for Bioscientists, Clinicians and Bioengineers” presented by: Mary Howard, Executive Director at Design Technologies LLC
In our monthly I2I (Invention to Innovation) event, OTC had the pleasure of hosting George Likourezos, J.D. and Dr. Carmella L. Stephens, Ph.D., J.D. from Carter, Deluca, & Farrell LLP. Georgetown University faculty and staff had the opportunity to learn more about IP protection for AI-implemented Life Sciences inventions and how University Entrepreneurs can prepare for commercialization of their technologies.
“Speed dating” for Innovation: OTC hosted an event where researchers and entrepreneurs with ideas had the opportunity to network with investors looking for ideas, enabling them to meet a large number of potential partners in a short amount of time
Research and Engagement
A Fast and Accurate COVID-19 Test: Georgetown University researchers have engineered a next generation pathogen detection system that has been shown to be extremely sensitive and specific and therefore to have extremely low false positive and false negative rates. It is as rapid or faster than other methods and can also be automated and used to test for multiple types of organisms simultaneously (“multiplexed”). We are kindly asking your support of this campaign that will allow researchers to use this groundbreaking technology to develop a high-fidelity rapid molecular test for detecting the COVID-19 virus. To support this campaign for a faster, more accurate COVID-19 test please visit the following link: https://www.givecampus.com. We appreciate your consideration of making a gift and sharing this important work with others who may also be interested in doing so.
Georgetown University (GU) continues to collaborate with George Washington University (GW) to help build the DC entrepreneurial community. We have been invited to join the “GWCAN” (More information can be found on the following link: https://giveandtakeinc.com/givitas-for-gwcan/). GW welcomes inventors, investors, new entrepreneurs and experienced entrepreneurs to explore the opportunities provided through the network. For more questions, contact the Office of Technology Commercialization, please call 202.687.7424 or email email@example.com.
Cures Within Reach has a new funding opportunity to support Diversity, Equity and Inclusion in biomedical research by providing at least 3 grants to US-based racial / ethnic minority PIs for their clinical repurposing trials. More info at https://bit.ly/cwrrfps.
Johnson & Johnson Innovation – JLABS @ Washington, DC is the newest Johnson & Johnson Innovation – JLABS life science and healthcare incubator. The state-of-the-art site will be open to entrepreneurs and innovators, and startups, focused on innovation across the healthcare spectrum, including pharmaceuticals, medical device, consumer and health tech. . Please review Johnson & Johnson Innovation’s areas of interests prior to applying to ensure your technology is aligned to what they are looking for at this time: https://jnjinnovation.com/partnering
For more information on J&J Innovation please visit the following link
Blue Knight | JLABS – Johnson & Johnson Innovation – JLABS is collaborating with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services to form Blue Knight. This collaboration aims to stimulate innovation and incubation of technologies that improve health security and response through companies focused on public health threats and emerging infectious diseases. For more information on Blue Knight please visit the following link.
National Academy of Inventors (NAI) Announces Launch of Free Online IP Course. With this course you will be able to:
-Explain the basics of intellectual property policies.
-Understand how intellectual property protections benefit individual creators, business owners, and entrepreneurs.
-Describe the relationship between intellectual property protection and economic growth.
-Discuss the historical origins of intellectual property law in the United States
More information can be found on the following link: NAI IP Course
- Nilotinib Appears Safe and Affects Biomarkers in Alzheimer’s Disease Clinical Trial
- New Drug Prevents Liver Damage, Obesity and Glucose Intolerance in Mice on High-Fat Diet
- Nilotinib Appears Safe in Parkinson’s Trial; Drug Thought to Allow Dopamine Replenishment
- Obese Mice Lose a Third of Their Fat Using a Natural Protein
- Researchers Find Inhibiting One Protein Destroys Toxic Clumps Seen in Parkinson’s Disease
- Other Stories Here
What is Technology Commercialization/ Technology Transfer?
Watch the Association of University Technology Managers (AUTM)’s site and video featuring the ins and outs of Technology Transfer and learn more about what is involved in its process.